Zacks Investment Research lowered shares of Amicus Therapeutics (NASDAQ:FOLD) from a hold rating to a sell rating in a research note issued to investors on Tuesday.
According to Zacks, “AMICUS THERAPEUTICS is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease. “
Several other equities research analysts have also issued reports on the stock. BidaskClub lowered shares of Amicus Therapeutics from a buy rating to a hold rating in a research report on Tuesday, February 13th. Leerink Swann lifted their price target on shares of Amicus Therapeutics from $20.00 to $24.00 and gave the stock an outperform rating in a research note on Thursday, February 8th. Robert W. Baird set a $20.00 price target on shares of Amicus Therapeutics and gave the stock a buy rating in a research note on Wednesday, February 7th. ValuEngine raised shares of Amicus Therapeutics from a sell rating to a hold rating in a research note on Friday, February 2nd. Finally, Cowen reissued a buy rating and set a $22.00 price target on shares of Amicus Therapeutics in a research note on Wednesday, January 10th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the company. The company has a consensus rating of Buy and a consensus price target of $19.06.
Shares of Amicus Therapeutics (FOLD) opened at $15.16 on Tuesday. Amicus Therapeutics has a 1 year low of $6.41 and a 1 year high of $17.40. The stock has a market cap of $2,520.00, a P/E ratio of -18.05 and a beta of 1.59. The company has a debt-to-equity ratio of 0.47, a quick ratio of 5.53 and a current ratio of 5.60.
Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.11). Amicus Therapeutics had a negative net margin of 769.03% and a negative return on equity of 71.06%. The company had revenue of $14.73 million for the quarter, compared to the consensus estimate of $14.50 million. equities research analysts anticipate that Amicus Therapeutics will post -1.26 EPS for the current year.
In related news, CEO John F. Crowley sold 65,581 shares of Amicus Therapeutics stock in a transaction on Thursday, December 21st. The shares were sold at an average price of $13.51, for a total value of $885,999.31. Following the transaction, the chief executive officer now directly owns 393,076 shares of the company’s stock, valued at $5,310,456.76. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Jay Barth sold 5,000 shares of Amicus Therapeutics stock in a transaction on Monday, March 12th. The stock was sold at an average price of $15.05, for a total transaction of $75,250.00. Following the completion of the transaction, the insider now directly owns 90,409 shares in the company, valued at $1,360,655.45. The disclosure for this sale can be found here. Insiders have sold 207,870 shares of company stock worth $3,066,112 over the last three months. Insiders own 3.40% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of FOLD. Sage Capital Advisors llc purchased a new position in shares of Amicus Therapeutics in the third quarter worth $154,000. Engineers Gate Manager LP purchased a new position in shares of Amicus Therapeutics in the third quarter worth $155,000. Neuberger Berman Group LLC purchased a new position in shares of Amicus Therapeutics in the third quarter worth $196,000. Great West Life Assurance Co. Can increased its stake in shares of Amicus Therapeutics by 40.2% in the third quarter. Great West Life Assurance Co. Can now owns 14,445 shares of the biopharmaceutical company’s stock worth $212,000 after buying an additional 4,145 shares during the period. Finally, Sterling Capital Management LLC purchased a new position in shares of Amicus Therapeutics in the third quarter worth $218,000.
WARNING: This story was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/03/14/amicus-therapeutics-fold-cut-to-sell-at-zacks-investment-research.html.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Get a free copy of the Zacks research report on Amicus Therapeutics (FOLD)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.